RPS6KB1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL123581	0.35	5/20
Linifanib (SCHEMBL93804)	1.00	4/20
Uprosertib (SCHEMBL168584)	1.00	4/20
SCHEMBL147422	0.66	4/20
SCHEMBL144979	0.56	4/20
SCHEMBL95142	1.00	3/20
SCHEMBL94964	0.79	3/20
SCHEMBL171201	0.69	3/20
SCHEMBL146734	0.67	3/20
SCHEMBL144651	0.67	3/20
SCHEMBL146677	0.67	3/20
SCHEMBL144378	0.66	3/20
SCHEMBL166239	0.65	3/20
SCHEMBL142020	0.65	3/20
SCHEMBL148704	0.62	3/20
SCHEMBL147730	0.61	3/20
SCHEMBL148478	0.61	3/20
SCHEMBL144118	0.61	3/20
SCHEMBL144615	0.61	3/20
SCHEMBL147715	0.61	3/20

Clinical trials — most relevant to RPS6KB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle	PHASE2	NOT_YET_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	PHASE1/PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	PHASE1/PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery	PHASE1	COMPLETED
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Exercise Effects on Cardiometabolic Health and Sestrin-2 in Hypertensive Obese Women	nan	NOT_YET_RECRUITING
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
NK Cell Deregulation in HBV Patients	nan	ACTIVE_NOT_RECRUITING
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a RPS6KB1 binder may also engage these)

Protein	Name	Similarity
Q6TJY3	—	1.000	Q6TJY3 →
Q8BSK8	—	1.000	Q8BSK8 →
P67999	—	1.000	P67999 →
P67998	—	1.000	P67998 →
Q9NAH6	—	1.000	Q9NAH6 →
Q39030	—	1.000	Q39030 →
Q9Z1M4	—	0.997	Q9Z1M4 →
Q66I46	—	0.996	Q66I46 →
Q2LZZ7	—	0.996	Q2LZZ7 →
STK38	Serine/threonine-protein kinase 38	0.995	landscape →
O08875	—	0.995	O08875 →
Q7TSE6	—	0.994	Q7TSE6 →
RPS6KB2	Ribosomal protein S6 kinase beta-2	0.993	landscape →
Q7TPS0	—	0.993	Q7TPS0 →
P08414	—	0.993	P08414 →
A1Z9X0	—	0.993	A1Z9X0 →
P09217	—	0.993	P09217 →
A2VDV2	—	0.993	A2VDV2 →
Q09137	—	0.992	Q09137 →
PRKCI	Protein kinase C iota type	0.992	landscape →
Q66JF3	—	0.992	Q66JF3 →
PRKAA2	5'-AMP-activated protein kinase catalytic subunit alpha-2	0.992	landscape →
P18654	—	0.992	P18654 →
Q28948	—	0.992	Q28948 →
O08605	—	0.992	O08605 →
RPS6KA3	Ribosomal protein S6 kinase alpha-3	0.992	landscape →
Q5EG47	—	0.991	Q5EG47 →
P22204	—	0.991	P22204 →
Q91VB2	—	0.991	Q91VB2 →
Q02111	—	0.991	Q02111 →